Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients

被引:29
作者
Oranje, WA
Sels, JPJE
Rondas-Colbers, GJWM
Lemmens, PJMR
Wolffenbuttel, BHR
机构
[1] Univ Hosp Maastricht, Dept Endocrinol & Metab, Maastricht, Netherlands
[2] Cardiovasc Res Inst Maastricht, Maastricht, Netherlands
关键词
type; 2; diabetes; LDL oxidation; atorvastatin; antioxidant vitamins;
D O I
10.1016/S0009-8981(01)00549-6
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Oxidative stress in diabetes increases lipid peroxidation, which stimulates the development of atherosclerosis. Methods: We investigated in a 3-month placebo-controlled study with 19 normocholesterolemic type 2 diabetic patients whether treatment with 10-mg atorvastatin influenced antioxidants and reduced LDL oxidizability, assessed by in vitro production of conjugated dienes after copper-induced LDL oxidation, Results: The lag phase, as a measure of the resistance of LDL to oxidation, did not change (62.8 +/- 8.2 respectively 59.6 +/- 9.7 min. p = n.s.). while conjugated dienes decreased (512 +/- 74 respectively 487 +/- 50 nmol, p = 0.012). Plasma alpha -tocopherol and ubiquinol levels decreased, while their ratios to LDL cholesterol remained stable. Conclusions: Atorvastatin favourably influences some parameters of LDL oxidation. Whether this effect is clinically relevant remains to be determined. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:91 / 94
页数:4
相关论文
共 12 条
[1]   Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients.: A 34-week, multicenter, open-label study [J].
Aguilar-Salinas, CA ;
Gómez-Pérez, FJ ;
Posadas-Romero, C ;
Vázquez-Chávez, C ;
Meaney, E ;
Gulías-Herrero, A ;
Guillén, LE ;
Vega, AA ;
Pérez, EM ;
Romero-Nava, LE ;
Gómez-Díaz, RA ;
Salinas-Orozco, S ;
Moguel, R ;
Novoa, G .
ATHEROSCLEROSIS, 2000, 152 (02) :489-496
[2]   Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS .
ATHEROSCLEROSIS, 1998, 138 (02) :271-280
[3]   SIMULTANEOUS DETERMINATION OF ALPHA-TOCOPHEROL AND RETINOL IN PLASMA OR RED-CELLS BY HIGH-PRESSURE LIQUID-CHROMATOGRAPHY [J].
BIERI, JG ;
TOLLIVER, TJ ;
CATIGNANI, GL .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1979, 32 (10) :2143-2149
[4]   Short-term treatment with low-dose pravastatin attenuates oxidative susceptibility of low-density lipoprotein in hypercholesterolemic patients [J].
Chen, MF ;
Hsu, HC ;
Lee, YT .
CARDIOVASCULAR DRUGS AND THERAPY, 1997, 11 (06) :787-793
[5]   DETERMINATION OF COENZYME-Q10, ALPHA-TOCOPHEROL AND CHOLESTEROL IN BIOLOGICAL SAMPLES BY COUPLED-COLUMN LIQUID-CHROMATOGRAPHY WITH COULOMETRIC AND ULTRAVIOLET DETECTION [J].
EDLUND, PO .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1988, 425 (01) :87-97
[6]   Oxidative stress and diabetic vascular complications [J].
Giugliano, D ;
Ceriello, A ;
Paolisso, G .
DIABETES CARE, 1996, 19 (03) :257-267
[7]   The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia [J].
Human, JA ;
Ubbink, JB ;
Jerling, JJ ;
Delport, R ;
Vermaak, WJH ;
Vorster, HH ;
Lagendijk, J ;
Potgieter, HC .
CLINICA CHIMICA ACTA, 1997, 263 (01) :67-77
[8]   DECREASED INVITRO OXIDIZABILITY OF LOW-DENSITY-LIPOPROTEIN IN HYPERCHOLESTEROLEMIC PATIENTS TREATED WITH 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS [J].
KLEINVELD, HA ;
DEMACKER, PNM ;
DEHAAN, AFJ ;
STALENHOEF, AFH .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1993, 23 (05) :289-295
[9]   Lipid peroxidation in type 2 diabetes: relationship with macrovascular disease? [J].
Oranje, WA ;
Rondas-Colbers, GJWM ;
Swennen, GNM ;
Wolffenbuttel, BHR .
NETHERLANDS JOURNAL OF MEDICINE, 1998, 53 (02) :61-68
[10]  
Velussi M, 1999, DIABETES NUTR METAB, V12, P407